WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has started manufacturing and distributing liquid concentrate products from its new, 51,000 square foot Grapevine, Texas plant.

Rockwell is now offering its full range of both liquid and dry dialysis concentrates in Texas and the surrounding markets in the South and Southwest. The Company's production of liquid acid concentrate in Texas provides its customers with a local supplier with a broad selection of dialysis solutions, further complementing its Dri-Sate Dry Acid Concentrate powder product line. The Company has been manufacturing its Dri-Sate and powder bicarbonate product lines with new automated manufacturing equipment in its Grapevine facility since October

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell, stated, “We are pleased that the Texas plant is fully operational. This plant is a significant step in our expansion and it will enable us to further expand our presence nationally. With the new equipment and added capacity, we anticipate improving our manufacturing efficiencies and reducing our per unit labor and delivery costs. We look forward to the opportunity to serve our customers and to introduce Rockwell to new customers in the South and Southwest with our extensive dialysis concentrate product lines.”

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has extended the expiration of its warrants for twelve months to January 26, 2003. The Company's publicly traded warrants had a trading term of three years and were to expire on January 26, 2002. However, the Company's Board of Directors approved the extension of the expiration date of the warrants for twelve months, expiring January 26, 2003.

Rockwell warrants trade under RMTIW with an exercise price of $4.50 per Common Share. The warrants have a call feature and may be redeemed by the Company provided the bid price of the Common Shares has been at least $7.00 for 20 consecutive trading days ending on the third day prior to the date the notice of redemption is given.

Rockwell recently reported that its revenues increased 25.8% for the first nine months of 2001.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported today that third quarter 2001 revenue was $2,259,000, an increase of 13.8% over the third quarter of 2000. Dialysis concentrate revenue, including the Company's Dri-Sate Dry Acid Concentrate, was up 20% over the third quarter of 2000.

For the nine months ended September 30, 2001, sales were $6,681,000, an increase of 25.8% compared to the same period a year ago. Dialysis concentrate sales were up over 30% as the Company realized a 32% increase in unit volume from its Dri-Sate Dry Acid Concentrate line, while its bicarbonate product line sales were up 43%.

While the Company realized increases in revenue, it incurred additional costs related to its new manufacturing facilities. As a result, the third quarter loss of ($460,000) increased by $153,000 over the prior year. Earnings per share was a loss of ($.07) per share in the third quarter of 2001 as compared to a loss of ($.06) per share in the third quarter of 2000.

For the nine months ended September 30, 2001, the Company's revenue increased by $1,372,000 over the first nine months of 2000. Net Loss was ($1,101,000) or an increase of $204,000. While gross profit improved by $105,000, additional costs of $400,000 related to the start-up and operation of the new manufacturing facilities offset the additional gross profit generated by a 25.8% increase in revenue. Loss per share for the first nine months of 2001 was ($.19) or ($.01) higher than in 2000.

“We are pleased with the gains we continue to make in our dialysis concentrate sales,” stated Mr. Robert L. Chioini, Chairman and CEO of the Company. “During the third quarter we initiated the commencement of operations at our two new facilities. While these new facilities have initially decreased our margins we anticipate that the streamlined processes and automated equipment that have been and continue to be put in place will result in improved margins in 2002 and beyond.”

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has begun manufacturing and distributing dry product from its Texas plant.

The Company has moved into the new 51,000 square foot manufacturing facility in order to accommodate its growing dialysis concentrate business. The facility has been designed to streamline manufacturing and distribution of all Rockwell products, with a specific, automated dry packaging area that will be used to manufacture and package the Company's Dri-Sate Dry Acid and Bicarbonate product lines. The new location will also manufacture Rockwell's Liquid Acid Concentrate product line, for which production is scheduled to begin early in the first quarter of 2002.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell, stated “This new facility is a significant step in our expansion. It will enable us to capture more market share, improve our manufacturing efficiencies and reduce our per unit labor and delivery costs going forward. Order fulfillment performance over the last month has met our expectations during this start-up phase. As we continue to expand our operations, we are committed to providing our customers with the high quality products and delivery that they expect.”

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 360,000 dialysis patients in the United States and the incidence of ESRD has increased 8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has entered into an exclusive distribution agreement with The International Co. for Industry & Trading, LTD. (ICIT), a distribution company located in Saudi Arabia, for the sale and distribution of its Dri-Sate Dry Acid Concentrate Mixing System as well as its bicarbonate concentrate products.

The agreement specifies ICIT to be the exclusive sales agent and distributor for Rockwell in Saudi Arabia. According to the agreement, ICIT will purchase a minimum quantity of the Company's Dri-Sate Dry Acid Concentrate and bicarbonate powder products over the next twenty-four months. The total revenue generated from the contract is expected to be between $750,000 and $800,000, although the revenue could be higher or lower depending on the mix of product ordered.

Robert L. Chioini, Chairman, CEO and President of Rockwell Medical Technologies, Inc., stated, “We're very pleased with this contract and with securing another channel of distribution into international markets. This is the third exclusive international supply contract we've completed this year and we anticipate securing others going forward. We continue to get strong interest for our Dri-Sate product line both inside and outside of the U.S. because of the positive economic advantages it offers.”

The Company recently reported that its first half 2001 sales increased 33% over the first half of 2000. The Company also reported that, in the first half of 2001, unit volumes of its Dri-Sate Dry Acid Concentrate product line were up 44% over the first half of 2000.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has signed a $1 million equipment lease financing agreement with GE Healthcare Financial Services. The Company will fund capital spending for equipment in its new production facilities in Texas and Michigan with the proceeds from the lease financing agreement.

Under the terms of the agreement, dated August 15, 2001, the Company can acquire up to $1,000,000 in manufacturing equipment with payment terms over 60 months. The Company will expand production capacity of its Dri-Sate Dry Acid Concentrate product line in support of unit volume growth, which has increased by 44% in the first half of 2001 as compared to the first half of 2000.

Mr. Thomas E. Klema, Vice President and Chief Financial Officer stated, “This lease transaction is integral to our overall financing plan in support of the Company's growth strategy. This will provide us with the capability to fund our upgraded manufacturing operations and expansion. We see dual benefits of both improved productivity and capacity expansion that will facilitate Rockwell's growth and margin improvement.”

“We are very pleased to have GE Healthcare support our growth strategy. With our overall sales up 33% in the first half of 2001 coupled with the strong market acceptance of our Dri-Sate Dry Acid Concentrate, we clearly see a need to expand our capacity to meet the growing demand for our products, both in the South with our new Texas facility and here in Michigan,” stated Mr. Robert L. Chioini, Chairman and CEO.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported today that second quarter 2001 revenue was $2,173,000, an increase of 29% over the second quarter of 2000. Revenue for the first half of 2001 was $1.1 million higher, or an increase of 33%, over the first half of 2000.

The Company achieved sales growth in all of its dialysis product lines with unit volumes of its Dri-Sate Dry Acid Concentrate up 44% in the second quarter of 2001 as compared to the second quarter of 2000. Similarly, sales of Rockwell's bicarbonate powder product line were up 45% compared to the year earlier quarter.

Earnings per share was a loss of ($.06) per share in the second quarter of 2001 as compared to a loss of ($.07) per share in the second quarter of 2000. While the Company realized increases in revenue, it incurred additional costs related to the Company's new manufacturing facilities. As a result the second quarter loss of ($356,000) was at the same level as the year earlier quarter despite the impact of higher revenue.

For the six months ended June 30, 2001, the Company's revenue increased by $1.1 million over the first six months of 2000. Rockwell's revenue growth in the first half of 2001 was driven primarily by its Dri-Sate Dry Acid Concentrate product sales to both new customers and expansion within current customers. Operating loss in the first half of 2001 of ($616,000) was at the same level as 2000's first half operating loss of ($613,000). Net loss of ($641,000) was $52,000 higher with the increase due to higher interest expense due to the Company's financing transactions. Loss per share in the first half of 2001 was ($.12), the same as 2000, with $.01 due to higher average shares outstanding in 2001.

“We are pleased with the significant revenue increases we have generated so far this year, both domestically and internationally,” stated Mr. Robert L. Chioini, Chairman and CEO of the Company. “Concentrate sales continue to gain momentum with Dri-Sate Dry Acid achieving a greater presence in the provider market. Going forward, we anticipate that production out of our Texas plant will begin this month and that eventually the efficiencies we gain from our automated systems will enable us to reduce our losses and handle increased production demand.”

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has been notified by Nasdaq that the Company has demonstrated compliance with Nasdaq's listing requirements and that the Company's common stock will continue to be listed on the Nasdaq SmallCap Market™. The Company had previously been notified by Nasdaq that its common stock could be de-listed from Nasdaq because the Company had failed to maintain a closing bid price of at least $1.00 per share. As this issue has been resolved satisfactorily, the matter is now closed.

Robert L. Chioini, Chairman, CEO and President of Rockwell Medical Technologies, Inc., stated, “We are very pleased that the Company received this communication. It further demonstrates the forward progress of the Company”.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has opened its new corporate headquarters and manufacturing facility located in Wixom, Michigan. The Company has moved into a new 52,000 square foot manufacturing facility in order to accommodate its growing dialysis concentrate business.

The new plant has been designed to streamline manufacturing and distribution of all Rockwell products with a specific dry packaging area that will be used to package the Company's Dri-Sate Dry Acid and Bicarbonate product lines. The new location will produce Rockwell's Dri-Sate Dry Acid Concentrate, Liquid Acid Concentrate, SteriLyte™ Liquid Bicarbonate and Powder Bicarbonate and also will be used to distribute the Company's expanding ancillary dialysis product line.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell, stated, “This new facility is a significant step in our expansion as it will enable us to substantially increase our production capacity and greatly improve our manufacturing efficiencies. This facility has been designed to allow us to automate our production processes and streamline our distribution which we expect will dramatically reduce our current labor costs going forward.” Mr. Chioini also stated, “Our business continues to expand and we see more of the dialysis concentrate market shifting to the dry acid product. This larger and more efficient facility coupled with our facility in Texas, which should be producing product this August, allows us to increase our production capacity five-fold."

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has entered into an exclusive distribution agreement with Optimum Trading Co., a medical company located in the Philippines, for the sale and distribution of its Dri-Sate Dry Acid Concentrate Mixing System as well as its bicarbonate concentrate products.

The agreement specifies Optimum Trading Co. to be the exclusive sales agent and distributor for Rockwell Medical Technologies, Inc. in the Philippines. According to the agreement, Optimum Trading Co. will purchase a minimum quantity of the Company's Dri-Sate Dry Acid Concentrate and bicarbonate powder products during the next twelve months. The annual revenue generated from the contract is estimated to be approximately $225,000, although the revenue could be slightly higher or lower depending on the mix of product ordered.

Robert L. Chioini, Chairman, CEO and President of Rockwell Medical Technologies, Inc., stated, “We feel very good about securing another channel of distribution into international markets. We continue to get strong interest for our Dri-Sate and bicarbonate product lines outside of the United States and this is another high-caliber distributor who will enable us to increase our international market presence.” Mr. Chioini further stated, "This supply contract coupled with the supply contract we recently secured in Pakistan should generate approximately $450,000 in sales revenue annually for Rockwell.”

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, said today that it has closed $500,000 in private equity funding, net of expenses. In addition, the Company has received Nasdaq approval to issue additional common shares pursuant to this offering without shareholder approval.

Rockwell Medical Technologies, Inc. is conducting a private placement of its common shares which may result in the issuance of a number of common shares in excess of 20% of the pre-transaction outstanding common shares of Rockwell. Because the issuance of common shares pursuant to this offering could exceed 20% of the pre-transaction outstanding common shares of Rockwell, Rockwell would be required to obtain shareholder approval of the transaction under Nasdaq Marketplace Rule 4350(i)(1)(d)(ii) unless granted an exception. Nasdaq has granted Rockwell an exception to this Rule pursuant to Nasdaq Marketplace Rule 4350(i)(2)(A). The audit committee of the Board of Directors of Rockwell has approved Rockwell's reliance upon this exception; therefore, Rockwell will not seek shareholder approval for this offering.

The offering is exempt from registration under the Securities Act of 1933. Under this offering Rockwell may issue up to 2 million common shares at a purchase price of $.50 per common share. Investors in the offering will receive unregistered common shares which may not be resold for a period of one year following the date they are acquired.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has entered into an exclusive distributorship agreement with Interex Company, a medical distribution corporation located in Karachi, Pakistan, for the sale and distribution of its Dri-Sate Dry Acid Concentrate Mixing System as well as its bicarbonate concentrate products.

The Agreement specifies Interex Company to be the exclusive sales agent and distributor for Rockwell Medical Technologies, Inc. in Pakistan. According to the Agreement, Interex Company will purchase a minimum of twelve ocean-freight containers of the Company's Dri-Sate Dry Acid Concentrate and bicarbonate powder products during the next twelve months.

Robert L. Chioini, Chairman, CEO and President of Rockwell Medical Technologies, Inc., stated, “Interex Company is an aggressive medical distribution company that has immediately been effective in securing Dri-Sate business in the Pakistan dialysis market and we are pleased to have them represent us in their country.” Mr. Chioini further stated, “Our penetration into the foreign markets with our Dri-Sate Dry Acid has been strong this year and we will continue to evaluate distributor relationships with high-caliber companies who will enable us to increase our international market share.”

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, said today that it received a Nasdaq Staff Determination on May 8, 2001, that the Company does not comply with the $1.00 minimum bid price requirements set forth in Marketplace Rule 4310(c)(4) and that its securities are subject to delisting from the Nasdaq SmallCap Market.

The Company has requested a hearing before a Nasdaq Listing Qualifications Panel to review the Staff Determination. Until the Panel reaches its decision, the Company's stock will remain listed and will continue to trade on the Nasdaq SmallCap Market. There can be no assurance the panel will grant the Company's request for continued listing.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported today that first quarter 2001 revenue was $2,249,000, an increase of 38% over the first quarter of 2000. First quarter revenue was the highest quarterly revenue in the Company's history.

While the Company achieved sales growth across all of its product lines, the Dri-Sate Dry Acid Concentrate product line continues to be the catalyst for generating new business. Sales increased by more than 40% from the first quarter of 2000 in the Company's Dri-Sate Dry Acid Concentrate product line.

Despite additional costs related to the Company's new plant, loss per share remained unchanged at $ (.05) per share, the same as the first quarter of 2000. The Company reported a loss of $286,000 in the first quarter as compared to a loss of $238,000 in the first quarter of 2000. However, the Company incurred costs related to plant expansion and start-up of $100,000 in the first quarter. In addition, the Company incurred $56,000 in non-cash charges related to common shares issued for investment banking and business development services.

Mr. Robert L. Chioini, Chairman, CEO, and President of Rockwell Medical Technologies, Inc. said, “The Company's results were in line with our expectations following a strong fourth quarter in 2000. This quarter we continued to experience strong demand for Dri-Sate Dry Acid as well as to attract new customers and expand our business within our current customer base.” Mr. Chioini also stated, "When we account for the additional expenses related to our second manufacturing plant in the Southwest along with the costs associated with our business development strategy we see solid progress in getting closer to achieving profitability."

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has signed a $2 million revolving credit loan facility with a financial institution.

Under the terms of the loan agreement, dated March 28, 2001, the credit facility has an initial sublimit of $1,000,000 that can be increased to $2,000,000 based on the growth of the Company's accounts receivable. The two year loan facility is secured by the Company's accounts receivable and certain other assets. The Company is obligated to pay interest at the rate of two points over the prime rate.

Mr. Thomas E. Klema, Vice President and Chief Financial Officer stated, “We are pleased to secure this financing which should provide Rockwell with the working capital resources it needs to support the expansion of business operations consistent with the Company's business strategy.”

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that an offer to acquire the Company has been received from a private investor group. Under the terms of the offer, the Company's shareholders would receive cash in the amount of $2.00 per share of common stock. The offer is subject to customary due diligence requirements.

The above offer and any other offers that may be received by the Company will be evaluated by the Company's Board of Directors. There can be no assurance that the above offer or that any other transaction will be approved by the Board of Directors. If this or any other transaction is approved by the Company's Board of Directors, approval by the Company's shareholders will be required.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported today that its fourth quarter 2000 revenue was $2,148,000 or 9.4% higher than the fourth quarter of 1999. Fourth quarter revenue was the highest in the Company's history. Fourth quarter loss per share narrowed to $.02 on a loss of $120,000 for the quarter.

Sales for 2000 were $7,457,000, an increase of 11.5% over 1999, reflecting substantial growth in the Company's Dri-Sate Dry Acid Concentrate product line. The Company's Dri-Sate sales increased by 95% and represent 24% of Company sales in 2000 compared to 14% in 1999. For the year 2000, the Company's operating loss was $1,017,000, a 5% improvement over 1999. Loss per share for 2000 was $ .21 as compared to a loss per share of $ .22 in 1999.

Mr. Robert L. Chioini, Chairman, CEO, and President of Rockwell Medical Technologies, Inc. said, "We are pleased to report record fourth quarter revenues as the growth in our Dri-Sate product line has been strong and has increased at a very fast rate. Our Dri-Sate sales increased an impressive 95% in 2000 and when we consider non-recurring Y2K buying in the last quarter of 1999, our underlying growth was much higher in 2000."

Mr. Chioini also said, "The Company's operating loss improved modestly over 1999 because of the continuing execution of our national growth strategy. We added additional production capacity and we increased investments in marketing and advertising. Nonetheless, we are very encouraged by our fourth quarter results and the high level of interest and strong demand that we are experiencing in the dialysis market for Dri-Sate. We expect that revenue growth, margin improvement and market share should continue to increase going forward."

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.